In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 8, 1998, Pages 573-575

  Clancy, C J ^a   Nguyen, M H ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; VORICONAZOLE;

ARTICLE; ASPERGILLUS; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; DRUG SENSITIVITY; FUNGICIDAL ACTIVITY; FUSARIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS; DRUG EVALUATION, PRECLINICAL; FUSARIUM; PYRIMIDINES; TRIAZOLES;

EID: 0031666585     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050133     Document Type: Article

References (16)

1. Anaissie E, Kantarjian H, Ro H, Hopfer R, Rolston K, Fainstein V, Bodey G: The emerging role of Fusarium infections in patients with cancer. Medicine (1988) 67:77-83
2. Denning, DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Review of Infectious Diseases (1990) 12:1147-1201
3. Sekhon AS, Padhye AA, Gurg AK, Ahmad H, Moledina N: In vitro sensitivity of medically significant Fusarium species to various antimycotics. Chemotherapy (1994) 40:239-244
4. Barry AL, Brown SD: In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrobial Agents and Chemotherapy (1996) 40:1948-1949
5. Belanger P, Nast C, Fratti R, Sanati H, Ghannoum M: Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrobial Agents and Chemotherapy (1997) 41:1840-1842
6. Nguyen MH, Yu YC: In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant Cryptococcus neoformans isolates. Antimicrobial Agents and Chemotherapy (1998) 42:471-472
7. Ruhnke M, Schmidt-Westhausen A, Trautmann M: In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy (1997) 41:575-577
8. Murphy M, Bernard EM, Ishimaru T, Armstrong D: Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy (1997) 41:696-698
9. Radford SA, Johnson EM, Warnock DW: In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mould pathogens. Antimicrobial Agents and Chemotherapy (1997) 41:841-843
10. Espinel-Ingroff A, Bartlett M, Bowden R, Chiu NX, Cooper C, Fothergill A, McGinnis MR, Menezes P, Messer SA, Nelson PW, Odds FC, Pasareil L, Peter J, Pfaller MA, Rex JH, Rinaldi MG, Shankland GS, Walsh TJ, Weitzman I: Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. Journal of Clinical Microbiology (1997) 35:139-143
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard M27-T. NCCLS, Villanova, PA (1995)
12. George D, Miniter P, Andriole VT: Efficacy of UK-109496, a new triaxole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy (1996) 40:86-91
13. Nguyen MH, Clancy CJ, Yu VL, Yu YC, Norris AJ, Snydman DA, Sutton DA, Rinaldi MG: Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. Journal of Infectious Diseases (1998) 177:425-430
14. McGinnis MR, Pasareil L, Sutton DA, Fothergill AW, Cooper CR, Rinaldi MG: In vitro evaluation of voriconazole against some clinically important fungi. Antimicrobial Agents and Chemotherapy (1997) 41:1832-1834
15. Denning DW, Venkateswarlu K, Oakley KL, Oakely MJ, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL: Itraconazole resistance in Aspergilllus fumigatus. Antimicrobial Agents and Chemotherapy (1997) 41:1364-1368
16. Walsh TJ, Melchor GP, Rinaldi MG, Lecciones J, McGough DA, Kelly V, Lee J, Callender D, Rubin M, Pizzo PA: Trichosporon beigelli, an emerging pathogen resistant to amphotericin B. Journal of Clinical Microbiology (1990) 28:1616-1622